Activist investor William Ackman is looking to take Allergan (NYSE:AGN) to court to ensure that the company won’t activate it’s "poison pill" when prospective acquirer Valeant Pharmaceuticals holds its shareholder meeting.
Valeant Pharmaceuticals
Medtronic, Johnson & Johnson store billions in cash in overseas subsidiaries | Medtech Wall Street news for the week of June 9, 2014
Allergan board members unanimously reject Valeant’s $53B offer
Stryker evaluates acquisition of orthopedics rival Smith & Nephew | Medtech Wall Street news for the week of June 2, 2014
What if Stryker bought Smith & Nephew?
May 29, 2014 by Brad Perriello
Stryker CEO Kevin Lobo yesterday admitted that his company was evaluating an acquisition of British orthopedics rival Smith & Nephew.